ADLM 2025

July 29-31 | Chicago | Illinois

Meet Us at Booth 260

We’re showcasing our next-gen PCR chemistry. If you're working on multiplexed diagnostics or novel assay development, let’s talk! Fill out the form below to connect with our team. Let’s explore how our chemistry can support your goals!

AdobeStock_547294500-1
Reinventing PCR for the Next Era of Molecular Diagnostics

We develop proprietary PCR chemistries that make multiplexing simpler, more affordable, and more accurate, empowering the next generation of diagnostics platforms. 

AdobeStock_514755724

Mission & Vision

Bringing Advanced Cancer Detection to the Frontline

Our mission is to democratize precision diagnostics. By enabling earlier cancer detection with simplified workflows and lower cost, our chemistry is designed to make a clinical impact at the point of care. 

AdobeStock_63739310

Technology Overview

Designed for Performance. Built for Real-World Use.

We’ve re-engineered PCR chemistry from the ground up to support high-fidelity multiplexing with minimal optimization. Compatible with qPCR and dPCR systems, our platform enables scalable panel development and streamlined workflows. By decoupling targets from detection channels, our platform enables at least 5-plex on qPCR and 30-plex on dPCR, with the potential for even higher levels, all with fewer tubes than conventional workflows.

Use Cases

Use Cases

Bringing Advanced Cancer Detection to the Frontline

Our platform opens the door to a wide range of high-impact diagnostic use cases, from oncology and infectious disease to sepsis, women’s health, and beyond. By combining signal amplification, multiplexing flexibility, and ease of integration, Signal’s chemistry empowers developers to design assays that address real clinical needs, without compromising performance or scalability.

Partnership Invitation

Science-Backed. Partner-Driven. 

We’re actively partnering with diagnostics companies, platform developers, and investors to accelerate the impact of our chemistry. Let’s build the future of molecular testing together.

Contact Us

About Us

We’re a biotech startup founded by molecular biologists and diagnostics engineers with a shared mission: to bring powerful diagnostic tools to the frontlines of care. Our interdisciplinary team is united by a commitment to rigorous science and real-world impact.

John Cunningham, CEO

John Cunningham, CEO

CEO and Founder
Founder & CEO of RapidBio
COO of Functional Fluidics
Technology Transfer at University of Michigan
Vladimir Makarov, Ph.D.

Vladimir Makarov, Ph.D.

CSO and Founder
Co-Founder and CSO of Rubicon Genomics (acquired by Takara) & Swift Biosciences (acquired by IDT)
50+ scientific publications and 23 patents
Adam McCoy Ph.D.

Adam McCoy Ph.D.

VP of Research and Development
Assoc. Director of Specialty Reagents, Bio-Rad
Director of R&D, LGC Biosearch Technologies
Head of Single-Cell Chemistry, Celsee Inc. (acquired by Bio-Rad)
Karl Spork, M.S.

Karl Spork, M.S.

Scientist 2
Staff Scientist, IDT
Sr Research Associate, Swift Biosciences
Niloufar Mertz, Ph.D.

Niloufar Mertz, Ph.D.

Senior Scientist
Senior Scientist, BioRad
Research Assistant, Kansas State University
Eric Pomaranski, Ph.D.

Eric Pomaranski, Ph.D.

Senior Scientist
Senior Scientist, BioRad
Postdoctoral Researcher, UC Davis
Emanuel

Emanuel Vacchiano, J.D., Ph.D.

Legal Counsel
Patent Attorney
Founder, Double Helix Law
Lead Patent Counsel, Thermo Fisher & Life Technologies
ContactUs